Literature DB >> 23895529

Age-related decline in melatonin and its MT1 receptor are associated with decreased sensitivity to melatonin and enhanced mammary tumor growth.

Steven M Hill1, Chi Cheng, Lin Yuan, Lulu Mao, Rolf Jockers, Bob Dauchy, David E Blask.   

Abstract

The pineal hormone melatonin (MLT) has potent anti-breast cancer activity, its actions are heavily mediated via the MT1 receptor and subsequent modulation of downstream signaling pathways including cAMP/PKA, Erk/MAPK, p38, and Ca2+/calmodulin. Also, via the MT1 pathway, MLT can repress the transcriptional activity of some mitogenic nuclear receptors including ERα, GR, and RORα, while potentiating the activity of other receptors (RARα and RXRα) involved in differentiation, anti-proliferation, and apoptosis. A review of the literature supports the view that MLT, via its MT1 receptor, can suppress all phases of breast cancer including initiation, promotion, and progression. During the fifth and sixth decades of life, the production of MLT diminishes, concurrently with an increase in the incidence of breast cancer. Inasmuch as MLT has been demonstrated to have anti-cancer activity, we hypothesized that there may be a causal link between the reduction in MLT production in the pineal gland and the incidence of breast cancer which increases with age. We designed this study to establish whether a truly inverse relationship exists between tissue-isolated mammary tumor growth in young (2 months), adult (12 months), and old (20 months) female Buffalo rats and the decrease in both MLT and the MT1 receptor with age, such that a causal link could be found. Serum MLT levels were measured in both the light and dark phases. A significant 29% decrease in serum MLT levels, measured at the nocturnal peak, was found in the adult and senescent rats (75% decrease) in comparison to that in young rats. In young rats, the nocturnal pineal gland MLT content exceeded daytime levels by 19-fold compared to a sevenfold increase in old mice. Also, the MT1 receptor was found to be significantly lower in the nighttime and early morning in the senescent rat uterus as compared to uteri from young and adult rats. Analysis of the rate of growth in transplanted, tissue-isolated, mammary tumors induced by N-nitroso-n-methyl-urea (NMU) showed a significant increase in the senescent rats, but not in the young or adult rats Additionally, diminished response to the inhibitory action on tumor growth of exogenous MLT was noted in senescent rats such that tumor growth was suppressed by only 33% compared to 48% and 66% in adult and young rats, respectively. The diminution of the response of tumors to exogenous MLT was found to correlate with reduced MT1 receptor expression in senescent compared to young and adult rats. These data suggest that the observed age-associated enhanced growth of tumors is related to the much reduced levels of MLT and its receptor in aged animals which reduce the sensitivity of tumors to inhibition by exogenous MLT.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23895529     DOI: 10.2174/1874609811306010016

Source DB:  PubMed          Journal:  Curr Aging Sci        ISSN: 1874-6098


  24 in total

1.  Urinary Melatonin in Relation to Postmenopausal Breast Cancer Risk According to Melatonin 1 Receptor Status.

Authors:  Elizabeth E Devore; Erica T Warner; A Heather Eliassen; Susan B Brown; Andrew H Beck; Susan E Hankinson; Eva S Schernhammer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-11-09       Impact factor: 4.254

2.  Melatonin protected cardiac microvascular endothelial cells against oxidative stress injury via suppression of IP3R-[Ca2+]c/VDAC-[Ca2+]m axis by activation of MAPK/ERK signaling pathway.

Authors:  Hang Zhu; Qinhua Jin; Yang Li; Qiang Ma; Jing Wang; Dandan Li; Hao Zhou; Yundai Chen
Journal:  Cell Stress Chaperones       Date:  2017-07-01       Impact factor: 3.667

3.  A Method for Perfusion of Tissue-Isolated Human Tumor Xenografts in Nude Rats to Investigate the Oncostatic Role of the Physiological Nocturnal Melatonin Signal.

Authors:  Robert T Dauchy; Steven M Hill; David E Blask
Journal:  Methods Mol Biol       Date:  2022

4.  Urinary excretion of melatonin and association with breast cancer: meta-analysis and review of the literature.

Authors:  Michelle Basler; Alexander Jetter; Daniel Fink; Burkhardt Seifert; Gerd A Kullak-Ublick; Andreas Trojan
Journal:  Breast Care (Basel)       Date:  2014-07       Impact factor: 2.860

Review 5.  Melatonin and Parkinson Disease: Current Status and Future Perspectives for Molecular Mechanisms.

Authors:  Omid Reza Tamtaji; Russel J Reiter; Reza Alipoor; Ehsan Dadgostar; Ebrahim Kouchaki; Zatollah Asemi
Journal:  Cell Mol Neurobiol       Date:  2019-08-06       Impact factor: 5.046

6.  Transdermal administration of melatonin coupled to cryopass laser treatment as noninvasive therapy for prostate cancer.

Authors:  Laura Terraneo; Paola Bianciardi; Eleonora Virgili; Elena Finati; Michele Samaja; Rita Paroni
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

7.  Expression of the MT1 melatonin receptor in ovarian cancer cells.

Authors:  Karolina Jablonska; Bartosz Pula; Agata Zemla; Christopher Kobierzycki; Witold Kedzia; Ewa Nowak-Markwitz; Marek Spaczynski; Maciej Zabel; Marzenna Podhorska-Okolow; Piotr Dziegiel
Journal:  Int J Mol Sci       Date:  2014-12-12       Impact factor: 5.923

8.  Somatic, positive and negative domains of the Center for Epidemiological Studies Depression (CES-D) scale: a meta-analysis of genome-wide association studies.

Authors:  A Demirkan; J Lahti; N Direk; A Viktorin; K L Lunetta; A Terracciano; M A Nalls; T Tanaka; K Hek; M Fornage; J Wellmann; M C Cornelis; H M Ollila; L Yu; J A Smith; L C Pilling; A Isaacs; A Palotie; W V Zhuang; A Zonderman; J D Faul; A Sutin; O Meirelles; A Mulas; A Hofman; A Uitterlinden; F Rivadeneira; M Perola; W Zhao; V Salomaa; K Yaffe; A I Luik; Y Liu; J Ding; P Lichtenstein; M Landén; E Widen; D R Weir; D J Llewellyn; A Murray; S L R Kardia; J G Eriksson; K Koenen; P K E Magnusson; L Ferrucci; T H Mosley; F Cucca; B A Oostra; D A Bennett; T Paunio; K Berger; T B Harris; N L Pedersen; J M Murabito; H Tiemeier; C M van Duijn; K Räikkönen
Journal:  Psychol Med       Date:  2016-03-21       Impact factor: 7.723

Review 9.  Repurposing Licensed Drugs for Use Against Alzheimer's Disease.

Authors:  Leslie C Norins
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 10.  Fundamental issues related to the origin of melatonin and melatonin isomers during evolution: relation to their biological functions.

Authors:  Dun-Xian Tan; Xiaodong Zheng; Jin Kong; Lucien C Manchester; Ruediger Hardeland; Seok Joong Kim; Xiaoying Xu; Russel J Reiter
Journal:  Int J Mol Sci       Date:  2014-09-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.